A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

计划入组 48 人 · 首次发布于 2021 年 3 月 8 日

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

计划入组 12 人 · 首次发布于 2020 年 12 月 31 日

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

计划入组 353 人 · 首次发布于 2023 年 3 月 22 日

BRII-196 + BRII-198

BRII-179/BRII-835

BRII-778

Brii Biosciences, Inc.

United States

Brii Biosciences (Hong Kong) Co. Limited

Hong Kong, China

BRII-B

Hong Kong, China

Brii Biosciences Licenses Novel Antibiotic BRII-693 to Joincare Group for Greater China Market

Brii Biosciences' Combination Therapy Shows Promise for Hepatitis B Functional Cure in Phase 2 Study

Brii Bio Acquires Full Rights to BRII-179 and Completes Enrollment for ENRICH Study in HBV